Peptide drug discovery platform company with proprietary peptide library, screening services, and robust internal drug development programs. Novel peptide technology platform uses cyclic peptides to encode and compress billions of sequences, including complete peptide libraries up to pentapeptide, and is capable of highly accurate and board screening with individually isolated peptides in HST 96-well format and supports functional assays (cell-based assay, in vivo assay, membrane-protein target screening capability). Formed by the Who’s Who in peptide drug discovery with a combined 75 years of biopharmaceutical R&D experience. They hope to leverage PepLib’s innovative platform to advance peptide drug discovery for the global biopharmaceutical community.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Oncology and Metabolic Diseases
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):